Nanopharmaceuticals: Innovative theranostics for the neurological disorders

Biomedical Reviews

Volumn 25, Issue , 2014, Pages 25-34

  Hassanzadeh, Parichehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nanoimaging; Nanomaterials; Nanotechnology; Neuronal regeneration; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; CARBON NANOTUBE; CERIUM OXIDE NANOPARTICLE; CHOLINESTERASE INHIBITOR; FULLERENE; MAGNETIC NANOPARTICLE; NANOPARTICLE; RIVASTIGMINE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; CELLULAR DISTRIBUTION; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE THERAPY; HUMAN; LIPOPHILICITY; MULTIPLE SCLEROSIS; NANOIMAGING; NANOPHARMACEUTICS; NERVE FIBER GROWTH; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; SPINAL CORD INFARCTION; TRANSDERMAL PATCH;

EID: 84949461660     PISSN: 1310392X     EISSN: 13141929     Source Type: Journal    
DOI: 10.14748/bmr.v25.1043     Document Type: Article

References (102)

1. Bramlett HM, Dietrich WD. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res 2007; 161: 125-141.DOI:10.1016/S0079-6123(06)61009-1.
2. Feynman RP. There’s plenty of room at the bottom. Eng Sci (Cal Tech) 1960; 594: 22-36.
3. Freitas Jr RA. Nanotechnology, nanomedicine and nanosurgery. Int J Surg 2005; 3: 243-246.DOI:10.1016/j.ijsu.2005.10.007.
4. Jain KK. Role of nanotechnology in developing new therapies for diseases of the nervous system. Nanomedicine (Lond) 2006; 1: 9-12.DOI:10.2217/17435889.1.1.9.
5. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006; 7: 65-74.DOI:10.1038/nrn1827.
6. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.DOI:10.1038/nrn1824.
7. De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: a strategy to overcome bloodbrain barrier. Curr Drug Metab 2012; 13: 61-69.DOI:10.2174/138920012798356943.
8. Hassanzadeh P, Fullwood I, Sothi S, Aldulaimi D. Cancer nanotechnology. Gastroenterol Hepatol Bed Bench 2011; 4: 63-69. PMCID: PMC4017405.
9. Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-855.DOI:10.1038/nrn2480.
10. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 2012; 64: 701-705.DOI:10.1016/j.addr.2011.12.006.
11. Qiu L, Zheng C, Jin Y, Zhu K. Polymeric micelles as nanocarriers for drug delivery. Expert Opin Ther Pat 2007; 17: 819-830.DOI:10.1517/13543776.17.7.819.
12. Sun NF, Meng QY, Tian AL, Hu SY, Wang RH, Liu ZX, et al. Nanoliposome mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation. Cancer Lett 2012; 315: 69-77.DOI:10.1016/j.canlet. 2011.10.010.
13. Jan E, Kotov NA. Successful differentiation of mouse neural stem cells on layer by layer assembled singlewalled carbon nanotube composite. Nano Lett 2007; 7: 1123-1128.DOI:10.1021/nl0620132.
14. Hassanzadeh P. Tissue engineering and growth factors. Updated evidence. Biomed Rev 2012; 23: 19-35.DOI: http://dx.doi.org/10.14748/bmr.v23.26
15. Fernandes R, Gracias DH. Self-folding polymeric containers for encapsulation and delivery of drugs. Adv Drug Deliv Rev 2012; 64:1579-1589.DOI:10.1016/j.addr.2012.02.012.
16. Hassanzadeh P. Computational modelling: Moonlighting on the neuroscience and medicine. Biomed Rev 2013; 24: 25-31.DOI: http://dx.doi.org/10.14748/bmr.v24.19
17. Lin H, Bhatia R, Lal R. Amyloid β protein forms ion channels: implications for Alzheimer’s disease pathophysiology. FASEB J 2001; 15: 2433-2444.DOI:10.1096/fj.01-0377com.
18. LeBlanc AC. The role of apoptotic pathways in Alzheimer’s disease neurodegeneration and cell death. Curr Alzheimer Res 2005; 2: 389-402.DOI:10.2174/156720505774330573.
19. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer’s disease: implications for neuroimaging and therapeutics. J Neurochem 2006; 97: 1700-1725.DOI:10.1111/j.1471-4159.2006.03989.x.
20. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004; 430: 631-639.DOI:10.1038/nature02621.
21. Arimon M, Diez-Perez I, Kogan MJ, Durany N, Giralt E, Sanz F, et al. Fine structure study of Aβ1-42 fibrillogenesis with atomic force microscopy. FASEB J 2005; 19: 1344-1346.DOI:10.1096/fj.04-3137fje.
22. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 2003; 116: 3339-3346.DOI:10.1242/jcs.00643.
23. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticlebased detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci USA 2005; 102: 2273-2276.DOI:10.1073/pnas.0409336102.
24. Irizarry MC. Biomark ers of Alzheimer disease in plasma. NeuroRx 2004; 1: 226-234.DOI:10.1602/neurorx.1.2.226.
25. Hassanzadeh P. New perspectives in biosensor technology. Gastroenterol Hepatol Bed Bench 2010; 3: 105-107.
26. Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 1997; 94: 9434-9439. PMCID: PMC23208.
27. Podolski IY, Podlubnaya ZA, Kosenko EA, Mugantseva EA, Makarova EG, Marsagishvili LG, et al. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J Nanosci Nanotechnol 2007; 7: 1479-1485. PMID:17450915.
28. Pai AS, Rubinstein I, Onyuksel H. PEGylated phospholipid nanomicelles interact with β-amyloid(1-42) and mitigate its β-sheet formation, aggregation and neurotoxicity in vitro. Peptides 2006; 27: 2858-2866.DOI:10.1016/j.peptides.2006.04.022.
29. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, et al. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm 2005; 59: 263-272.DOI:10.1016/j.ejpb.2004.07.009.
30. Liu G, Garrett G, Men P, Zhu X, Perry G, Smith MA. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochem Biophys Acta 2005; 1741: 246-252.DOI:10.1016/j.bbadis.2005.06.006.
31. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006; 406: 189-193.DOI:10.1016/j.neulet.2006.07.020
32. Ikeda K, Okada T, Sawada S, Akiyoshi K, Matsuzaki K. Inhibition of the formation of amyloid β-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett 2006; 580: 6587-6595.DOI:10.1016/j.febslet.2006.11.009.
33. Boridy S, Takahashi H, Akiyoshi K, Maysinger D. The binding of pullulan modified cholesterylnanogels to Aβ oligomers and their suppression of cytotoxicity. Biomaterials 2009; 30: 5583-5591.DOI:10.1016/j.biomaterials.2009.06.010.
34. Taylor M, Moore S, Mourtas S, Niarakis A, Re F, Zona C, et al. Effect of curcumin-associated and lipid ligandfunctionalized nanoliposomes on aggregation of the Alzheimer’s Aβ peptide. Nanomedicine 2011; 7: 541-550.DOI:10.1016/j.nano.2011.06.015.
35. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1‑42 peptide. Biomaterials 2011; 32: 1635-1645.DOI:10.1016/j.biomaterials.2010.10.027.
36. Yang Z, Zhang Y, Yang Y, Sun L, Han D, Li H, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine 2010; 6: 427-441.DOI:10.1016/j.nano.2009.11.007
37. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaële D, et al. Translocation of poly(ethylene glycol‑co‑hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007; 8: 793-799.DOI:10.1021/bm060711a.
38. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res 2008; 1200: 159-168.DOI:10.1016/j.brainres.2008.01.039.
39. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010; 76: 189-199.DOI:10.1016/j.ejpb.2010.07.007.
40. Schrag A, Quinn NP, Ben-Shlomo Y. Heterogeneity of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77: 275-276. PMCID: PMC2077583.
41. Lefaucheur JP, Gurruchaga JM, Pollin B, von Raison F, Mohsen N, Shin M, et al. Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson’s disease: correlation with intra-operative multi-unit recordings but not with the type of anaesthesia. Eur Neurol 2008; 60: 186-99.DOI:10.1159/000148246.
42. Paul G, Meissner W, Rein S, Harnack D, Winter C, Hosmann K, et al. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson’s disease. Exp Neurol 2004; 185: 272-280.DOI:10.1016/S0014-4886(03)00363-7.
43. Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T, et al. Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005; 76: 1217-1221.DOI:10.1136/jnnp.2004.057893.
44. Fraix V, Houeto JL, Lagrange C, Le Pen C, Krystkowiak P, Guehl D, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77: 443-449.DOI:10.1136/jnnp.2005.077677.
45. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow up. Neurology 2002; 58: 396-401.DOI: 1526-632X.
46. Moro E, Esselink RJ, Benabid AL, Pollak P. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 2002; 125: 2408-2417.DOI: http://dx.doi.org/10.1093/brain/awf249.
47. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251-256.DOI:10.1016/j.ejpb.2008.08.021.
48. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O’Malley KL. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001; 7: 243-246.DOI:10.1016/S1353-8020(00)00064-X.
49. Lotharius J, Duga LL, O’Malley KL. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 1999; 1284-1293. PMID: 9952406.
50. Lin AM, Chyi BY, Wang SD, Yu HH, Kanakamma PP, Luh TY, et al. Carboxyfullerene prevents iron-induced oxidative stress in rat brain. J Neurochem 1999; 72: 1634-1640.DOI:10.1046/j.1471-4159.1999.721634.x.
51. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004; 15: 50-60.DOI:10.1021/bc034164r.
52. Witt J, Marks WJ. An update on gene therapy in Parkinson’s disease. Curr Neurol Neurosci Rep 2011; 11: 362-370.DOI:10.1007/s11910-011-0197-8.
53. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003; 14: 1-12.DOI:10.1089/10430340360464660.
54. Nitta SK, Numata K. Biopolymer-Based Nanoparticles for Drug/Gene Delivery and Tissue Engineering. Int J Mol Sci 2013; 14: 1629-1654.DOI:10.3390/ijms14011629.
55. Yurek DM, Flectcher AM, Kowalczyk TH, Padegimas L, Cooper MJ. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transp 2009; 18: 1183-1196.DOI:10.3727/096368909X12483162196881.
56. Mazzatenta A, Giugliano M, Campidelli S, Gambazzi L, Businaro L, Markram H, et al. Interfacing neurons with carbon nanotubes: electrical signal transfer and synaptic stimulation in cultured brain circuits. J Neurosci 2007; 27: 6931-6936.DOI:10.1523/JNEUROSCI.1051-07.2007.
57. Hassanzadeh P, Hassanzadeh A. Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists. Eur Neuropsychopharmcol 2011; 21: 905-917.DOI:10.1016/j.euroneuro.2011.01.002.
58. Hassanzadeh P, Rahimpour S. The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology 2011; 215: 129-141.DOI:10.1007/s00213-010-2120-4.
59. Hassanzadeh P, Hassanzadeh A. Effects of different psychotropic agents on the central nerve growth factor protein. Iran J Basic Med Sci 2010; 13: 202-209. ISSN: 2008-3866.
60. Hassanzadeh P, Hassanzadeh A. Implication of NGF and endocannabinoid signalling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential. Psychopharmacology 2013; 229: 571-578.DOI:10.1007/s00213-013-3111-z.
61. Hassanzadeh P, Hassanzadeh A. The CB1 receptormediated endocannabinoid signaling and NGF: the novel targets of curcumin. Neurochem Res 2012; 37: 1112-1120.DOI:10.1007/s11064-012-0716-2.
62. Chen W, Xiong Q, Ren Q, Guo Y, Li G. Can aminofunctionalized carbon nanotubes carry functional nerve growth factor? Neural Regen Res 2014; 9: 285-292.DOI:10.4103/1673-5374.128225.
63. Andrews R. Neuroprotection at the nanolevel-Part I Introduction to nanoneurosurgery. Ann NY Acad Sci 2007; 1122: 169-184.DOI:10.1196/annals.1403.012.
64. Lugo K, Miao X, Rieke F, Lin LY. Remote switching of cellular activity and cell signaling using light in conjunction with quantum dots. Biomed Opt Exp 2012; 3: 447-454.DOI:10.1364/BOE.3.000447.
65. Comston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.DOI:10.1016/S0140-6736(02)08220-X.
66. Henderson APD, Barnett MH, Parratt JDE, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 739-753.DOI:10.1002/ana.21800.
67. Heta Y, Kumaki K, Hifumi H, Citterio D, Tanimoto A, Suzuki K. Gadolinium containing photochromic micelles as potential magnetic resonance imaging traceable drug carriers. Photochem Photobiol 2012; 88: 876-883.DOI:10.1111/j.1751-1097.2012.01124.x.
68. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide feasibility and safety in humans. Circulation 2012; 5: 509-517.DOI:10.1161/CIRCIMAGING.112.972596.
69. Zhang HF, Maslov K, Stoica G, Wang V. Functional photoacoustic microscopy for high-resolution and noninvasive imaging. Nat Biotech 2006; 24: 24848-24851.DOI:10.1038/nbt1220.
70. Zivadinov R, Ramanathan M, Dolic K, Marr K, Karmon Y, Siddiqui AH, et al. Chronic cerebrospinal venous insufficiency inmultiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother 2011; 11: 1277-1294.DOI:10.1586/ern.11.117.
71. Srikanth M, Kessler JA. Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol 2012; 8: 307-318.DOI:10.1038/nrneurol.2012.76.
72. Cellot G, Cilia E, Cipollone S, Rancic V, Sucapane A, Giordani S, et al. Carbon nanotubes might improve neuronal performance by favouring electrical shortcuts. Nat Nanotech 2009; 4: 126-133.DOI:10.1038/nnano.2008.374.
73. Ali SS, Hardt JI, Dugan LL. SOD Activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study. Nanomedicine 2008; 4: 283-294.DOI:10.1016/j.nano.2008.05.003.
74. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O’Malley KL. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001; 7: 243-246.DOI:10.1016/S1353-8020(00)00064-X.
75. Dai H, Navath RS, Balakrishnan B, Guru BR, Mishra MK, Romero R, et al. Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. Nanomedicine 2010; 5: 1317-1329.DOI:10.2217/nnm.10.89.
76. Khawaja AM. The legacy of nanotechnology: revolution and prospects in neurosurgery. Int J Surg 2011; 9: 608-614.DOI:10.1016/j.ijsu.2011.10.002.
77. Bramlett HM, Dietrich WD. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res 2007; 161: 125-141.DOI:10.1016/S0079-6123(06)61009-1.
78. Aloe L, Bianchi P, De Bellis A, Soligo M, Rocco ML. Intranasal nerve growth factor bypasses the blood-brain barrier and affects spinal cord neurons in spinal cord injury. Neural Regen Res 2014; 9:1025-1030.DOI:10.4103/1673-5374.133161.
79. Cummings BJ, Uchida N, Tamaki SJ, Salazar DL, Hooshmand M, Summers R, et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Nat Acad Sci USA 2005; 102: 14069-14074.DOI:10.1073/pnas.0507063102.
80. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, et al. Genetically engineered mesenchymal stem cells reduce behavioural deficits in the YAC 128 mouse model of Huntington’s disease. Behav Brain Res 2010; 214: 193-200.DOI:10.1016/j.bbr.2010.05.023.
81. Binan L, Ajji A, De Crescenzo G, Jolicoeur M. Approaches for neural tissue regeneration. Stem Cell Rev Rep 2014; 10: 44-59.DOI:10.1007/s12015-013-9474-z.
82. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009; 61: 467-477.DOI:10.1016/j.addr.2009.03.007.
83. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dyeloaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 2009; 5: 1862-1868.DOI:10.1002/smll.200900389.
84. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315-319.DOI:10.1002/ajh.21656.
85. Xia L, Wan H, Hao SY, Li DZ, Chen G, Gao CC, et al. Co-transplantation of neural stem cells and Schwann cells within poly (L-lactic-coglycolic acid) scaffolds facilitates axonal regeneration in hemisected rat spinal cord. Chin Med J 2013; 126: 909-917. PMID: 23489801.
86. Senpan A, Caruthers SD, Rhee I, Mauro NA, Pan D, Hu G, et al. Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano 2009; 3: 3917-3926.DOI:10.1021/nn900819y.
87. Woerly S, Petrov P, Sykova E, Roitbak T, Simonova Z, Harvey AR. Neural tissue formation within porous hydrogels implanted in brain and spinal cord lesions: ultrastructural, immunohistochemical, and diffusion studies. Tissue Eng 1999; 5: 467-488. PMID:10586102.
88. Yoo HS, Kim TG, Park TG. Surface-functionalized electrospun nanofibers for tissue engineering and drug delivery. Adv Drug Deliv Rev 2009; 61: 1033-1042.DOI:10.1016/j.addr.2009.07.007.
89. Huang SH, Chien TC, Hung KY. Selective deposition of electrospun alginate-based nanofibers onto cellrepelling hydrogel surfaces for cell-based microarrays. Curr Nanosci 2011; 7: 267-274.DOI: http://dx.doi. org/10.2174/157341311794653703.
90. Liu T, Xu J, Chan BP, Chew SY. Sustained release of neurotrophin-3 and chondroitinase ABC from electrospun collagen nanofiber scaffold for spinal cord injury repair. J Biomed Mater Res A 2012; 100: 236-242.DOI:10.1002/jbm.a.33271.
91. Rochkind S, Shahar A, Fliss D, El-Ani D, Astachov L, Hayon T, et al. Development of a tissue engineered composite implant for treating traumatic paraplegia in rats. Eur Spine J 2006; 15: 234-245.DOI:10.1007/s00586-005-0981-8.
92. Bruijn LI, Cudkowicz M. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother 2006; 6: 417-428.DOI:10.1586/14737175.6.3.417.
93. Schubert D, Dargusch R, Raitano J, Chan SW. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys Res Commun 2006; 342: 86-91.DOI:10.1016/j.bbrc.2006.01.129.
94. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as a vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008; 70: 633-640.DOI:10.1016/j.ejpb.2008.05.008.
95. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009; 71: 161-172.DOI:10.1016/j.ejpb.2008.09.003.
96. Müller RH, Maeder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.DOI:10.1016/S0939-6411(00)00087-4.
97. Kumbhar DD, Pokharkar VB. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: Physicochemical investigations. Colloids Surf A Physicochem Eng Asp 2013; 416: 32-42.
98. Rahman HS, Rasedee HS, How CW, Abdul AB, Zeenathul NA, Othman HH, et al. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomed 2013; 8: 2769-2781.DOI:10.2147/IJN.S54346.
99. Mendes AI, Silva AC, Catita JAM, Cerqueira F, Gabriel C, Lopes CM. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: Improving antifungal activity. Colloids Surf B: Biointerfaces 2013; 111: 755-763.DOI:10.1016/j.colsurfb.2013.05.041.
100. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008: 70: 633-640.DOI:10.1016/j.ejpb.2008.05.008.
101. Shenoy VS, Vijay IK, Murthy RS. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol 2005; 57: 411-421. PMID: 15831200.
102. Bondì ML, Azzolina A, Craparo EF, Botto C, Amore E, Giammona G, et al. Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J Nanobiotech 2014; 12: 21.DOI:10.1186/1477-3155-12-21.